search
for
 About Bioline  All Journals  Testimonials  Membership  News


Journal of Postgraduate Medicine
Medknow Publications and Staff Society of Seth GS Medical College and KEM Hospital, Mumbai, India
ISSN: 0022-3859
EISSN: 0022-3859
Vol. 56, No. 2, 2010, pp. 163-167
Bioline Code: jp10044
Full paper language: English
Document type: Review Article
Document available free of charge

Journal of Postgraduate Medicine, Vol. 56, No. 2, 2010, pp. 163-167

 en Posaconazole
Bhattacharya, M.; Rajeshwari, K. & Dhingra, B.

Abstract

Posaconazole is a novel second-generation Triazole oral antifungal agent. It is highly effective in the prophylaxis of invasive fungal infections in immunocompromised patients. It is used as a first-line agent as well as for salvage therapy in invasive fungal infections including aspergillosis, oropharyngeal and esophageal candidiasis. It has a good adverse effect profile. With the rising incidence of invasive fungal infections due to the HIV pandemic and medical advancements in transplantation and cancer therapy, these features make posaconazole a valuable addition in the family of antifungal agents.

Keywords
Posaconazole, invasive fungal infections, candidiasis, immunocompromised

 
© Copyright 2010 Journal of Postgraduate Medicine.
Alternative site location: http://www.jpgmonline.com

Home Faq Resources Email Bioline
© Bioline International, 1989 - 2024, Site last up-dated on 01-Sep-2022.
Site created and maintained by the Reference Center on Environmental Information, CRIA, Brazil
System hosted by the Google Cloud Platform, GCP, Brazil